.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

James Blachly, MD

Articles

Treatment Strategies for Relapsed/Refractory AML Patients

December 20th 2024

Panelists discuss how the latest NCCN guidelines for relapsed/refractory acute monocytic leukemia (R/R AML) outline targeted therapy options outside clinical trials, and explore treatment approaches based on patient fitness, actionable biomarkers, and prior therapies, highlighting the impact of first remission duration and genetic abnormalities on treatment sequencing.

Dr. Blachly on ctDNA as a Biomarker in Hairy Cell Leukemia

October 25th 2019

James Blachly, MD, discusses the role of circulating tumor DNA as a biomarker for patients with hairy cell leukemia.